Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenuePayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Shares IssuedShares OutstandingShares Outstanding
Ratios

Drugs Made In America Acquisition (DMAA) Shares Outstanding (2024 - 2025)

Drugs Made In America Acquisition filings provide 2 years of Shares Outstanding readings, the most recent being $10.7 million for Q4 2025.

  • Quarterly Shares Outstanding rose 8.72% to $10.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.7 million through Dec 2025, up 8.72% year-over-year, with the annual reading at $10.7 million for FY2025, 8.72% up from the prior year.
  • Shares Outstanding hit $10.7 million in Q4 2025 for Drugs Made In America Acquisition, up from $10.5 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $10.7 million in Q4 2025 and bottomed at $9.9 million in Q4 2024.